Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Trends in hysterectomy-corrected uterine cancer mortality rates during 2002 to 2015: mortality of nonendometrioid cancer on the rise?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gastrointestinal toxicity during induction treatment for childhood acute lymphoblastic leukemia: The impact of the gut microbiota

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Human Papillomavirus Same Genotype Persistence and Risk: A Systematic Review

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Jesper Bonde
  • Arno Floore
  • Ditte Ejegod
  • Frederique J Vink
  • Albertus Hesselink
  • Peter M van de Ven
  • Anja Oštrbenk Valenčak
  • Helle Pedersen
  • Saskia Doorn
  • Wim G Quint
  • K Ulrich Petry
  • Mario Poljak
  • Grazyna Stanczuk
  • Kate Cuschieri
  • Silvia de Sanjosé
  • Maaike Bleeker
  • Johannes Berkhof
  • Chris J L M Meijer
  • Daniëlle A M Heideman
  • Elia Alcaniz
  • Beate Rothe
  • Montserrat Torres Hortal
  • Marta Del Pino
  • Ramya Bhatia
View graph of relations

In human papillomavirus (HPV) cervical cancer screening, cytology is used as triage to counter the low specificity of HPV testing. VALID-SCREEN is a EU-multicenter, retrospective study conducted to evaluate the clinical performance of the FAM19A4/miR124-2 methylation-based molecular triage test as a substitute or addition to cytology as reflex testing of HPV screen positive women. FAM19A4/miR124-2 methylation test (QIAsure Methylation Test) was evaluated in 2384 HPV-positive cervical screening samples, from women 29-76 years of age, derived from four EU countries. Specimens were collected in ThinPrep or SurePath media, HPV-status, concurrent cytology, and histology diagnosis were provided by the parent institutes. The control population consisted of women with no evidence of disease within 2 years of follow-up. A total of 899 histologies were retrieved; 527 showed no disease, 124 CIN2 (5.2%), 228 CIN3 (9.6%) and 20 cervical cancers (0.8%); 19 of 20 screen-detected cervical cancers were found methylation-positive (sensitivity 95%). Overall specificity of FAM19A4/miR124-2 methylation test was 78.3% (n = 2013; 95%CI: 76-80). The negative predictive value of hrHPV positive, methylation-negative outcomes were 99.9% for cervical cancer (N = 1694; 95%CI: 99.6-99.99), 96.9% for ≥CIN3 (95%CI: 96-98), and 93.0% for ≥CIN2 (95%CI: 92-94). Overall sensitivity for CIN3 using FAM19A4/miR124-2 methylation test was 77% (n = 228; 95%CI: 71-82). CIN3 sensitivity was uniform between centers independent of sample collection medias, DNA extraction methods and HPV screening tests. Being objectively reported compared to the subjectivity of cytology, equally performing across settings and screening methods, the FAM19A4/miR124-2 methylation constitute an alternative/supplement to cytology as triage method to be investigated in real-life pilot implementation.

Original languageEnglish
JournalInternational Journal of Cancer
Volume148
Issue number2
Pages (from-to)396-405
Number of pages10
ISSN0020-7136
DOIs
Publication statusPublished - 15 Jan 2021

Bibliographical note

© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.

    Research areas

  • biomarker, cervical carcinoma, cervical screening, DNA hypermethylation, human genome methylation, human papillomavirus

ID: 60979167